MeSH tree: N06.850.520.830.998.825
For patients with human epidermal growth factor receptor 2-positive (HER2-positive) metastatic or locally advanced unresected gastroesophageal adenocarcinoma (mGEA), zanidatamab and chemotherapy, with or without tislelizumab, ...
Jan 12, 2026
0
8
Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small ...
Sep 7, 2025
0
36
The National Cancer Center Research Institute in Tokyo reports that a newly isolated gut bacterium, designated Hominenteromicrobium strain YB328, mobilizes specialized dendritic cells to strengthen the impact of PD-1 blockade ...
Researchers from RWJBarnabas Health and Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, as well as Tufts Medical Center and The University of Manchester, have ...
Jun 20, 2025
0
22
First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according ...
May 30, 2025
0
21
For patients with diffuse gliomas, tumor-related epilepsy (TRE) is not a strong prognostic factor, according to a study published in the May issue of Brain and Behavior.
May 21, 2025
0
15
Results from a new Phase 3 trial published in the journal npj Precision Oncology found that a cancer stem cell test can accurately choose more effective treatments and lead to improved outcomes for patients with platinum-resistant ...
Apr 4, 2025
0
47
An international team of researchers, including experts from the University of Adelaide, has found genomic testing and targeted therapies for patients with advanced cancer could improve survival rates by up to 40%.
Apr 2, 2025
0
15
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to ...
Jan 27, 2025
0
19
For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) leads to improved survival compared with preoperative chemoradiotherapy, ...
Jan 23, 2025
0
17
